title: Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder.
abstract: BACKGROUND
  Various studies suggest the hippocampus and serotonergic systems are important in the pathology of bipolar disorder (BD). We therefore measured hippocampal serotonergic markers in post-mortem tissue from BD and control subjects.
  
  
  METHODS
  The density and affinity of [3H]citalopram binding to the serotonin transporter (SERT), as well as the density of the 5HT(2A), 5HT(1A), 5HT(1D) and 5HT(1F) receptors were measured.
  
  
  RESULTS
  The density of SERT and 5HT receptors was no different in BD. There was a significant decrease in the affinity of [3H]citalopram binding to SERT in the stratum lacunosum-moleculare (S(lac)) in BD (K(d) mean+/-S.E.M.=4.3+/-0.8 vs. 1.9+/-0.3 nM).
  
  
  CONCLUSIONS
  This study was completed using relatively small cohorts.
  
  
  CONCLUSIONS
  There are no generalised changes in hippocampal serotonergic markers in the hippocampus from subjects with BD. There is a decreased affinity of radioligand binding to S(lac) SERT in subjects with BD.
authors.affiliation: The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia. b.dean@papyrus.mhri.edu.au
authors.forename: Brian
authors.initials: B
authors.lastname: Dean
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Scarr
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Pavey
authors.forename: David
authors.initials: D
authors.lastname: Copolov
mesh_terms: D000345:Affinity Labels / Q000493:pharmacokinetics; D001665:Binding Sites; D015415:Biomarkers; D001714:Bipolar Disorder / Q000378:metabolism* / Q000473:pathology*; D002352:Carrier Proteins / Q000378:metabolism; D002452:Cell Count; D015283:Citalopram / Q000493:pharmacokinetics*; D046508:Culture Techniques; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007650:Ketanserin / Q000493:pharmacokinetics; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011985:Receptors, Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000493:pharmacokinetics; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics*; D018170:Sumatriptan / Q000493:pharmacokinetics
chemical_list: D000345:Affinity Labels; D015415:Biomarkers; D002352:Carrier Proteins; D015283:Citalopram; D007650:Ketanserin; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D018170:Sumatriptan; C493230:SLC6A4 protein, human